Document:

EX-10.44

 Exhibit 10.44 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENT 

This Amendment No. 1 to Amended and Restated License Agreement (collectively with exhibits and appendices hereto, the
“Amendment”) is entered into on June 30th, 2015 (“Execution Date”) by and between the Technion Research and Development Foundation Ltd. having a place of business at Senate house, Technion City, Haifa Israel
(“Licensor”), acting on behalf of itself and the Technion- Israel Institute of Technology, and Applied Immune Technology Ltd., a company organized under the laws of the State of Israel and having a place of business at
Gutwirth Industrial Park, Technion City, Haifa 32000 Israel (“Company”). 
 WHEREAS, Licensor is the wholly-owned
subsidiary of Technion – Israel Institute of Technology (the “Technion”) and serves as its technology licensing arm; and 

WHEREAS, the parties entered into an Amended and Restated License Agreement dated as of May 21, 2014 (the “License
Agreement”); and 
 WHEREAS, the Parties have agreed to amend the License Agreement to clarify that TCRL compounds directed
to a peptide that is presented by [***] within the scope of the technology licensed to Company under the License Agreement; and 

WHEREAS, notwithstanding the foregoing, the parties have agreed that the Existing Patents (as defined below) are expressly excluded
from the scope of the license and AIT shall have no right or interest therein; and 
 WHEREAS, Company wishes to fund research in the
field of [***] in the laboratory of [***] (“Researcher”) at the Technion on the terms and subject to the conditions set forth below. 

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

 

	 	1.	 Amendment to License Agreement. Effective as of March 1, 2005, the definitions of “TCRL”
and “TCRL Compound” in the License Agreement shall be deleted and replaced by the following: 

“TCRL” means any biological or non-biological binding moiety [***]. 

“TCRL Compound” means a specific compound comprising a biological or
non-biological binding moiety [***]. 
 For clarity, except as otherwise set forth in this
Amendment, references in the Agreement to MHC shall be deemed to relate to both [***] as appropriate. For clarity, notwithstanding the terms of this Amendment or anything to the contrary set forth in the License Agreement, the patent applications
listed in Exhibit A to this Amendment (“Existing [***]”), which, to TRDF’s knowledge, are the sole patent applications filed in the name of the Researcher or Technion as of the date hereof relating to [***] complexes recognized
by T-cells, are expressly excluded from the scope of the licenses granted AIT under the License Agreement, are expressly excluded from the definition of “Licensed Patent Rights” under the License
Agreement, and AIT shall have no right or interest therein. 

	 	2.	 The following clause is hereby added at the end of existing Section 14.4(b) of the License Agreement:

 “Notwithstanding anything to the contrary set forth herein, for purposes of Section 14,
Company’s and/or Licensor’s activities in relation [***] shall be considered separately from Company’s and/or Licensor’s activities in relation to other Licensed Technology, {ii) a breach of Company’s and/or
Licensor’s obligations with respect to [***] shall not give Licensor the right to terminate Company’s exclusive rights in other Licensed Technology, (iii) only where Company commits a material breach of its
obligations in respect of [***] under this Agreement and fails to cure such breach [***] after receiving written notice thereof from Licensor, Licensor may terminate the exclusive license granted in [***] under
Section 5.1(a)(ii) and (iv) Company shall not have any rights to deduct or withhold payments and shall not deduct or withhold payments otherwise due to Licensor with respect to any Licensed Technology (which
does not include [***]) due to any potential liability or indebtedness in connection with [***] and Company shall not have any rights to deduct or withhold payments and shall not deduct or withhold payments otherwise due to Licensor
with respect to [***] due to any potential liability or indebtedness in connection with any Licensed Technology (which does not Include [***]). 
  

	 	3.	 Funded Research; Inclusion of [***] in Licensed Technology. 

 

	 	(a)	 Company agrees to fund research in Researcher’s laboratory at the Technion relating to [***] complexes
recognized by T-Cells in an [***] for a period [***] from the Execution Date of this Amendment (“Initial Research Period”). Such amount may be increased, subject to agreement on a research
plan, by the parties’ mutual agreement in their discretion. Company may cease providing such research funding in the event of breach under the License Agreement, if [***] ceases to be available to perform the research or if the License
Agreement is terminated for any reason. Company may, but shall not be obligated, to continue such funding in its discretion for additional periods, subject to the Parties mutual agreement in writing. 

The Parties further agree that, subject to the provisions of Section 2 above, the diligence requirements under Section 6 of the
License Agreement shall apply to [***] mutatis mutandis. 
  

	 	(b)	 Without limiting the Parties rights under the License Agreement, during the Initial Research Period and any
subsequent period in which Company funds research relating to [***] in the Researcher’s laboratory at the Technion, all results or inventions relating to [***] created by or under the supervision of the Researcher at the Technion ([***])
(collectively, “Research Results”) will be automatically deemed Researcher Improvements under the license Agreement, provided that Research Results that are specific TCRL Compounds ([***]) will be Joint Researcher
Improvements. 

  

	 	(c)	 The terms of the License Agreement relating to Researcher Improvements and Joint Researcher Improvements (as
applicable) apply equally to Research Results, including without limitation the provisions of Section 7 (Consideration for Grant of License). For clarity, provided the funding commitment in paragraph (a) above is met, the terms of this
paragraph apply to Research Results even if aggregate research funding provided by Company to Technion for research in Researcher’s laboratory is [***]. 

  

	 	(d)	 During the Initial Research Period and any subsequent period in which Company funds research relating to [***]
in the Researcher’s laboratory at the Technion, the Researcher undertakes that he will first notify and coordinate with the Company in writing before engaging in collaborations with third parties or using third party intellectual property in
connection with [***] research, and if the Company objects in writing during the [***] period following receipt of said notice he will either find an alternative acceptable to the Company or abstain from performing the research using

	 	
funding from the Company. It is hereby agreed by the Parties that the limitations contained in this subclause (d) shall not affect any research by or under the supervision of the Researcher
which commenced prior to the Effective Date in the Researcher’s laboratory at the Technion, provided that in each case (i) no funding from Company is used in connection with such research; and (ii) for collaborations with third
parties or use of third party intellectual property in connection with [***] research performed following the Execution Date, Company has received written notice of such. 

 

	 	(e)	 Notwithstanding the terms of paragraphs (b} and (c) above, the side letter between Licensor and the [***]
investors named therein [***] will not apply to elements of Licensed Technology that are [***] complexes relating to TCRL’s. Solely with respect to the foregoing, the following representations and warranties replace the representations and
warranties set forth in Section 12.1 of the License Agreement: 

 Licensor hereby represents and warrants to
the Company that (i) neither Licensor nor Technion has granted or will grant any rights in or to Licensed Technology, or Joint Researcher Improvement which are inconsistent with the rights granted to Company under this Agreement; and
(ii) the Licensor and Technion have not entered and will not enter into any agreement pursuant to which any party has ownership1 license or other rights in or to Company Inventions. 

 

	 	4.	 General. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings
ascribed to such terms under the License Agreement. The terms of this Amendment shall be deemed an integral part of the License Agreement. Other than as specifically amended herein, the provisions, terms and conditions of the license Agreement shall
remain unchanged and in full force and effect. 

 [Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their
duly authorized representatives as of the date first written above. 
  

									
	Applied Immune Technologies Ltd.	 		 	Technion Research and Development Foundation Ltd.
					
	By:	 	 /s/ Mira Peled-Kamar
	 		 	By:	 	 /s/ [Authorized Signatory]

	Name:	 	Mira Peled-Kamar	 		 	Name:	 	[Authorized Signatory]
	Title:	 	CEO	 		 	Title:	 	Authorized Signatory

 I, the undersigned, hereby confirm that I have read this Amendment No. 1 to License Agreement, that its contents are
acceptable to me and that I will act in accordance with the obligations applicable to me set forth herein. 
  

	
	 /s/ [Authorized Signatory]

	[***]EX-10.45

 Exhibit 10.45 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

AMENDMENT No. 2 TO 

AMENDED AND RESTATED LICENSE AGREEMENT 

This Amendment No. 2 to Amended and Restated License Agreement (this “Amendment”) dated as of
January 13, 2016 (the “Effective Date”), is entered into among Technion Research and Development Foundation Ltd. (“TRDF”), Applied Immune Technology Ltd. (“AIT”), and Adicet Bio Inc.
(“Adicet”) (TRDF, AIT and Adicet, collectively, the “Parties”), with respect to the following facts: 

TRDF and AIT are parties to the Amended and Restated License Agreement entered into on May 21st, 2014, and its Amendment
No. 1 dated June 30th, 2015, as may be further amended or restated from time to time (collectively, the “License Agreement”). All capitalized terms used, but not defined, herein shall have the respective
meanings set forth in the License Agreement. 
 The Parties desire to amend the License Agreement in certain respects and agree to the other
provisions of this Amendment. 
 Now, therefore, the Parties hereby agree as follows: 

1.    The License Agreement hereby is amended as follows: 

1.1    For purposes of Section 2 (“Definitions”), Section 7 (“Consideration for Grant of
License”) (as amended hereby) and Section 8 (“Reports; Payments; Records”) of the License Agreement and the defined terms as used therein, “Licensed Product” shall mean any product (a) which entirely
or partially (1) comprises or incorporates technology developed by or in collaboration with, licensed to, controlled or otherwise acquired by Adicet Bio Inc. (“Adicet”) or its Subsidiaries or Affiliates controlled by it
(without regard to the [***] requirement in the definition of “Subsidiary” (a “Downstream Affiliate”) or by AIT or its Subsidiaries or its Downstream Affiliates (including but not limited to the Licensed Technology and Joint
Researcher Improvements) (the “Adicet Licensed Product” and the “AIT Licensed Product”, respectively), or (2) the making, using or selling of which falls within the scope of the Licensed Technology or Joint Researcher
Improvements, and (b) for which an IND is granted on or prior to December 31, 2024. 
 In addition, the following
defined terms under Section 2 of the License Agreement shall be deleted and the corresponding provisions in the License Agreement shall be revised accordingly: “Additional Ingredient”, “Combination Product”,
“Royalty Cessation Date” and “Valid Claim”. 
 1.2    Section 7.1 of the License Agreement is
amended and restated to read in full as follows: 
 “7.1 Royalties. During the Royalty Period (as defined below), in the
event that Company itself or any Subsidiary or Downstream Affiliates of Company or Adicet will sell Licensed Products, Company shall pay Licensor a running royalty equal [***] of Net Sales by Company itself or any Subsidiary or Downstream Affiliates
of Company or Adicet. Notwithstanding anything to the contrary herein, Company or Adicet shall not owe to Licensor (and Licensor shall not be entitled to receive) any royalties on any sales by Adicet, AIT or their respective Subsidiaries or
Downstream Affiliates to each other but shall not derogate from any obligations to pay royalties on sales to third parties.” 

  
 1 

 1.3    Section 7.2 of the License Agreement is amended and restated to
read in full as follows: 
 “7.2 Sublicense Receipts. During the Royalty Period, in the event that a Sublicensee itself
or any Subsidiary or Affiliates of Sublicensee will sell Licensed Products, Company shall pay Licensor the lesser of (a) [***] sales of Licensed Products by Sublicensee itself or any Subsidiary or Affiliates of Sublicensee (as defined in
the sublicense agreement), or (b) except if a Sublicensee is an Affiliate of Company or Adicet (in which case only the preceding subsection (a) will apply), [***] of the amounts received by Company or Adicet or its Subsidiary
or Downstream Affiliate in the form of royalties on net sales of Licensed Products by Sublicensee itself or any Subsidiary or Affiliates of Sublicensee (as defined in the sublicense agreement). Company shall owe no other sublicense-related payments.
Notwithstanding anything to the contrary herein, Company or Adicet shall not owe to Licensor (and Licensor shall not be entitled to receive) royalties based on any amounts received by Adicet, AIT or their respective Subsidiaries or Downstream
Affiliates from each other, but shall not derogate from any obligations to pay royalties on sales to third parties.” 

1.4    Section 7.3 of the License Agreement is amended and restated to read in full as follows: 

“7.3 Royalty Period and No Adjustments. “Royalty Period” shall mean, with respect to each Licensed Product,
[***] after the First Commercial Sale of such Licensed Product, on a Licensed Product-by-Licensed Product basis. There shall be no adjustments or offsets to the royalty obligations hereunder (including, without limitation, adjustments or offsets for
combination products, third party royalty stacking, generic products, M&A or time based adjustments). Other than the payments expressly set forth in Sections 7.1 and 7.2, Adicet, AIT and their respective Affiliates shall not owe to Licensor
any payments in connection with the sale of Licensed Products or the sublicense of the Licensed Technology or Joint Researcher Improvements. For the avoidance of any doubt, nothing herein shall derogate from the commitment by the Company to pay for
the preparation, filing, prosecution, protection and maintenance of all patents and patent applications within the Licensed Technology and Joint Researcher Improvement Patent Rights in accordance with Section 9 to the License Agreement
and to fund the research in Researcher’s laboratory at the Technion relating to [***] complexes recognized by T-Cells during the Initial Research Period as stated in Amendment No. 1.” 

1.5    Unless terminated in accordance with the terms of the Agreement, it is hereby clarified that the term of the
Agreement as set forth in Section 14.1 of the License Agreement shall not be sooner than the “Royalty Period” as such term is defined herein. 

1.6    In the event of a termination pursuant to Section 14.3(a) (“Termination without Cause”), the
obligations of Company to pay royalties under Section 7 of the License Agreement and Adicet to pay royalties under Section 2 of this Amendment shall survive such termination with respect to those Licensed Products for which
an IND was granted prior to the date of such termination ([***]) as well as any obligations which in accordance with the License Agreement are intended to survive termination. 

2.    Adicet shall be bound by the obligations under Section 7 (“Consideration for Grant of License”) (as
amended hereby) and Section 8 (“Reports; Payments; Records”) of the License Agreement with respect to sales of any Licensed Product by Adicet, its Subsidiaries or Downstream Affiliates, or Sublicensees, its Subsidiaries or
Affiliates. It is hereby clarified that this provision shall not be affected by any termination or assignment of the License Agreement or any disposition of AIT or AIT’s assets or securities. 

  
 2 

 3.    Without derogating or amending the provisions of Section 2
above in any manner and in addition thereto, Adicet shall also be jointly and severally bound by the obligations of AIT under the License Agreement, including without limitation Section 7 (“Consideration for Grant of License”)
(as amended hereby) and Section 8 (“Reports; Payments; Records”) of the License Agreement, with respect to the Licensed Products – only for so long as Adicet directly or indirectly owns or controls AIT; provided, however,
without limiting Adicet’s obligation under Section 2 of this Amendment, upon the sale, transfer or change of control to a third party of control of AIT, such third party thereafter shall be jointly and severally bound by the
obligations of AIT under the License Agreement, including without limitation Section 7 (“Consideration for Grant of License”) (as amended hereby) and Section 8 (“Reports; Payments; Records”) of the License
Agreement. Nothing herein shall relieve Adicet from its obligations under Section 2 of this Amendment regarding Adicet Licensed Products. Adicet additionally shall remain bound by all the terms and conditions of any sublicense agreement
with AIT. 
 4.    If a third party acquires Adicet and its Subsidiaries or Downstream Affiliates in an M&A
Transaction, then Licensed Products shall exclude all products of the acquiror or its Affiliates (other than Adicet and its Subsidiaries and Downstream Affiliates) provided that such products do not comprise or incorporate technology owned or
controlled by Adicet or its Subsidiaries or Downstream Affiliates, or by AIT or its Subsidiaries or Downstream Affiliates (including without limitation the Licensed Technology and Joint Researcher Improvements). 

5.    If a third party acquires AIT and its Subsidiaries or Downstream Affiliates in an M&A Transaction, then Licensed
Products shall exclude all products of the acquiror or its Affiliates (other than AIT and its Subsidiaries and Downstream Affiliates) provided that such products do not comprise or incorporate technology owned or controlled by Adicet or its
Subsidiaries or Downstream Affiliates, or by AIT or its Subsidiaries or Downstream Affiliates (including without limitation the Licensed Technology and Joint Researcher Improvements) and further provided that in such M&A Transaction, Adicet
shall not be relieved from its obligations under Section 2 of this Amendment regarding Adicet Licensed Products without TRDF’s written consent which shall not be unreasonably withheld. 

6.    Without limiting Adicet’s obligations under this Amendment, Adicet shall have the option to acquire and assume
from AIT all rights and obligations of Company set forth in the License Agreement with respect to all but not part of the licensed intellectual property and technology thereunder. 

7.    As of the date hereof, the License Agreement is in full force and effect, and TRDF is not aware of any facts or
circumstances that may indicate that AIT has not used Commercially Reasonable Efforts to discover or develop at least one Licensed Product. 

8.    Other than as specifically amended herein, the provisions, terms and conditions of the License Agreement shall
remain unchanged and in full force and effect. 
 9.    Nothing herein shall be construed (a) as providing Adicet
or AIT or their respective Affiliates with any ownership or license rights to any intellectual property beneficially owned by TRDF other than the intellectual property subject to the License Agreement, or (b) as providing TRDF with any
ownership or license rights to any intellectual property beneficially owned by Adicet or AIT or their respective Affiliates. 

  
 3 

 The effectiveness of this Amendment is conditioned upon the closing of that certain Series A
Preferred Stock Purchase Agreement dated as of January 13, 2016, regarding, and the closing of, the acquisition by Adicet of AIT. To the extent such closings do not occur by June 30, 2016, this Amendment shall be void and
null, ab initio. 
  

			
	Accepted and Agreed:
	
	Adicet Bio Inc.
		
	By:	 	 /s/ Aya Jakobovits

	Title:	 	President & CEO
		
	Date:	 	January 13, 2016
	
	Accepted and Agreed:
	
	Applied Immune Technology Ltd.
		
	By:	 	 /s/ Mira Peled-Kamar

	Title:	 	CEO
		
	Date:	 	January 13, 2016
	
	Accepted and Agreed:
	
	Technion Research and Development Foundation Ltd.
		
	By:	 	 /s/ [Authorized Signatory]

	Title:	 	[Authorized Signatory]
		
	Date:	 	January 13, 2016
	
	Accepted and Agreed:
	
	 /s/ Authorized Signatory

	[***]
		
	Date:	 	January 13, 2016

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]